Thomas Ebeling - Qiagen NV Independent Member of the Supervisory Board
| QGEN Stock | USD 42.33 0.24 0.57% |
Executive
Thomas Ebeling is Independent Member of the Supervisory Board of Qiagen NV since 2021.
| Age | 61 |
| Tenure | 3 years |
| Address | Hulsterweg 82, Venlo, Netherlands, 5912 PL |
| Phone | 31 77 355 6600 |
| Web | https://www.qiagen.com |
Qiagen NV Management Efficiency
The company has return on total asset (ROA) of 0.0484 % which means that it generated a profit of $0.0484 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0257 %, meaning that it created $0.0257 on every $100 dollars invested by stockholders. Qiagen NV's management efficiency ratios could be used to measure how well Qiagen NV manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Qiagen NV's Return On Capital Employed is very stable compared to the past year. As of the 22nd of November 2024, Return On Assets is likely to grow to 0.06, while Return On Tangible Assets are likely to drop 0.09. At this time, Qiagen NV's Asset Turnover is very stable compared to the past year.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Nicholas Childs | IQVIA Holdings | N/A | |
| Sheetal Parmar | Natera Inc | N/A | |
| Andrea Spannheimer | IQVIA Holdings | N/A | |
| Gary Passman | NeoGenomics | N/A | |
| George Cardoza | NeoGenomics | 62 | |
| MD MBA | Aclaris Therapeutics | N/A | |
| David Green | ICON PLC | N/A | |
| Jonathan Curtain | ICON PLC | 48 | |
| Sarah Demey | Neogen | N/A | |
| Zarak Khurshid | Guardant Health | N/A | |
| Nigel Clerkin | ICON PLC | 50 | |
| John Saia | Guardant Health | 51 | |
| Greg Sparks | NeoGenomics | N/A | |
| Alistair Grenfell | IQVIA Holdings | N/A | |
| Danielle Menture | Sotera Health Co | N/A | |
| Jon Jacobsen | Aclaris Therapeutics | N/A | |
| Reinilde MD | Medpace Holdings | 63 | |
| Kathleen Hoffman | Sotera Health Co | N/A | |
| Phil Grinnell | Natera Inc | N/A | |
| Derek MD | NeoGenomics | N/A | |
| David Naemura | Neogen | 54 | |
Management Performance
| Return On Equity | 0.0257 | ||||
| Return On Asset | 0.0484 |
Qiagen NV Leadership Team
Elected by the shareholders, the Qiagen NV's board of directors comprises two types of representatives: Qiagen NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Qiagen. The board's role is to monitor Qiagen NV's management team and ensure that shareholders' interests are well served. Qiagen NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Qiagen NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephane Bancel, Independent Member of the Supervisory Board | ||
| John Gilardi, VP of Corporate Communications and Investor Relations | ||
| Jonathan Sheldon, Senior Vice President Member of the Executive Committee | ||
| Fernando Beils, Senior Area | ||
| JeanPascal Viola, Senior Development | ||
| Elaine Mardis, Independent Member of the Supervisory Board | ||
| Thomas Ebeling, Independent Member of the Supervisory Board | ||
| Roland Sackers, Managing Director, Chief Financial Officer, Member of the Executive Committee | ||
| Elizabeth Tallett, Independent Member of the Supervisory Board | ||
| Stephany Foster, Senior Resources | ||
| Thomas Neidert, Vice Treasury | ||
| Thomas Theuringer, Director Communications | ||
| Antonio Santos, Senior Operations | ||
| Metin Colpan, Co-Founder, Supervisory Director and Chairman of Science and Technology Committee | ||
| Thierry Bernard, Chief Executive Officer, Managing Director, Member of the Executive Board | ||
| Toralf Haag, Independent Member of the Supervisory Board | ||
| Thomas Schweins, Senior Vice President - Human Resources, Strategy & Marketing Services | ||
| Ross Levine, Independent Member of the Supervisory Board | ||
| Lawrence Rosen, Independent Chairman of the Supervisory Board |
Qiagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Qiagen NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0257 | ||||
| Return On Asset | 0.0484 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 9.79 B | ||||
| Shares Outstanding | 222.26 M | ||||
| Shares Owned By Insiders | 2.24 % | ||||
| Shares Owned By Institutions | 87.79 % | ||||
| Number Of Shares Shorted | 3.57 M | ||||
| Price To Earning | 24.32 X |
Pair Trading with Qiagen NV
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Qiagen NV position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Qiagen NV will appreciate offsetting losses from the drop in the long position's value.Moving together with Qiagen Stock
| 0.64 | A | Agilent Technologies Earnings Call This Week | PairCorr |
| 0.77 | ME | 23Andme Holding | PairCorr |
| 0.72 | VALN | Valneva SE ADR Downward Rally | PairCorr |
Moving against Qiagen Stock
| 0.76 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.75 | BMY | Bristol Myers Squibb | PairCorr |
| 0.57 | EXEL | Exelixis | PairCorr |
| 0.54 | FLGC | Flora Growth Corp | PairCorr |
| 0.46 | KTTAW | Pasithea Therapeutics | PairCorr |
The ability to find closely correlated positions to Qiagen NV could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Qiagen NV when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Qiagen NV - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Qiagen NV to buy it.
The correlation of Qiagen NV is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Qiagen NV moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Qiagen NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Qiagen NV can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qiagen NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Qiagen Stock, please use our How to Invest in Qiagen NV guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qiagen NV. If investors know Qiagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qiagen NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.255 | Earnings Share 0.45 | Revenue Per Share 8.841 | Quarterly Revenue Growth 0.055 | Return On Assets 0.0484 |
The market value of Qiagen NV is measured differently than its book value, which is the value of Qiagen that is recorded on the company's balance sheet. Investors also form their own opinion of Qiagen NV's value that differs from its market value or its book value, called intrinsic value, which is Qiagen NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qiagen NV's market value can be influenced by many factors that don't directly affect Qiagen NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qiagen NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Qiagen NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qiagen NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.